Abstract:Abstract The approval of an increasing number of molecularly targeted therapies in cancer creates an opportunity to contemplate combinations of such agents. This is particularly important because single agents typically exhibit limited activity and very often drug resistance in clinic. A current challenge is to identify appropriate rational combinations that combine distinct mechanisms to elicit maximal anti-tumor activity and to overcome drug resistance. Tivozanib (formerly AV-951 or KRN951) is a small molecule VEGFR inhibitor that has been shown to be active in a phase 2 clinical trial in RCC. Tivozanib inhibits VEGFR 1, 2 and 3 activity at picomolar concentrations (IC50 of 0.21, 0.16 and 0.24 nM respectively), Rapamycin targets mTOR, a protein involved in integrating nutrient availability with cellular functions, including proliferation. mTOR is also known to promote hypoxia inducible factor (HIF1) activity, which in turn drives angiogenesis, such that in some settings, rapamycin is thought to elicit anti-tumor activity through an anti-angiogenic mechanism. We studied the activity of tivozanib and rapamycin as single agents and in combination in a genetically engineered HER2 driven breast adenocarcinoma model where multiple primary tumors have been expended in vivo for mechanisms of response and drug resistance biomarker exploration. These tumors exhibit significant variation in response to tivozanib. In one group of tumors, tivozanib as a single agent induced complete tumor growth inhibition persisting for at least 6 weeks. Rapamycin at a clinically relevant dose also induced complete tumor growth inhibition. However, histological analysis after short (5 days) or longer (35 days) term treatment revealed distinct mechanisms of action, i.e., anti-VEGF for tivozanib but direct antiproliferation for rapamycin. Combination of tivozanib and rapamycin resulted in substantially greater overall tumor reduction with evidence of both anti-angiogenic and anti-proliferation activities. Importantly, after 6 weeks of treatment, regions of drug resistance start to emerge in either rapamycin or tivozanib monotherapy tumors. However no evidence of drug resistance was observed with the tivozanib/rapamycin combination. To further explore the combination activity in resistant tumors, we established a resistant sub-line by long term tivozanib treatment. Both tivozanib and rapamycin as single agents resulted in only partial tumor growth inhibition. The combination treatment induced complete growth inhibition with evidence of both angiogenesis inhibition and direct antitumor effect. The distinct mechanisms of action of these two agents, along with the apparent suppression of drug resistance suggest that tivozanib and mTOR inhibitors may represent an attractive rational combination treatment for solid malignancies. At this point, an on-going phase 1B trial in RCC has shown that tivozanib can be combined with temsirolimus at full doses of both agents. An all oral combination of tivozanib and everolimus, an oral mTOR inhibitor, is also being developed for RCC and other tumors. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):B143.

Targeting mTOR and survivin concurrently potentiates radiation therapy in renal cell carcinoma by suppressing DNA damage repair and amplifying mitotic catastrophe

[RAD001 Reverses Radio-Resistance and Exerts Synergistic Tumor Inhibition with 5-Fluorouracil].

Inhibition of Mtor Enhances Radiosensitivity of Lung Cancer Cells and Protects Normal Lung Cells Against Radiation

Outcomes of Targeted Therapy Plus Immunotherapy and High-Dose Stereotactic Ablative Body Radiotherapy (SABR) for Metastatic Renal Cell Cancer Patients.

Combinations of Mtorc1 Inhibitor RAD001 with Gemcitabine and Paclitaxel for Treating Non-Hodgkin Lymphoma.

Dual Targeting of Akt and mTORC1 Impairs Repair of DNA Double-Strand Breaks and Increases Radiation Sensitivity of Human Tumor Cells

Combination with Stereotactic Body Radiotherapy Offers a Promising Strategy to Overcome Resistance to Immunotherapy in Advanced Renal Cell Cancer

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the Mtorc1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo

Optimizing targeted drug selection in combination therapy for patients with advanced or metastatic renal cell carcinoma: A systematic review and network meta-analysis of safety

Abstract B143: Distinct Antitumor Mechanisms of VEGFR Inhibitor Tivozanib (AV-951) and Mtor Inhibitor Rapamycin Support Rational Combination for Solid Tumors to Overcome Drug Resistance

ERK Inhibitor Enhances Everolimus Efficacy Through the Attenuation of Dntp Pools in Renal Cell Carcinoma

Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells

Synergic Effect of Metformin and Everolimus on Mitochondrial Dynamics of Renal Cell Carcinoma

Targeted Inhibition of Mammalian Target of Rapamycin (mtor) Enhances Radiosensitivity in Pancreatic Carcinoma Cells.

MicroRNAs targeted mTOR as therapeutic agents to improve radiotherapy outcome

Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage

Recent pharmacological approaches for the treatment of renal cell carcinoma

Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma

A Combination therapy using an mTOR inhibitor and Honokiol effectively induces autophagy through the modulation of AXL and Rubicon in renal cancer cells and restricts renal tumor growth following organ transplantation

Mammalian Target of Rapamycin Inhibitors Resistance Mechanisms in Clear Cell Renal Cell Carcinoma